Scientist of Fortune
Contributor since: 2017
Latest Articles
Intellia Therapeutics: Left Behind The Cas9 Excitement
Catalyst Pipeline Portfolio Updates - Strong Start For The Portfolio
resTORbio: Stimulating Immune Responses In Elderly Populations
A Bombshell Day For Athersys: Earnings, Partnership, And New Indications
Sangamo Therapeutics: Great Start To 2018 - $3 Billion KITE/Gilead Announcement
Selling Into A Void - Athersys Moves In Ignorance
Doubling Survival Time For Pancreatic Cancer - ARMO BioSciences
Tetraphase Failures - Look Beyond The Panic
Atossa Genetics: Wait And See
Chimerix - Years Behind The Competition
Pluristem - Hidden Treasures And Sudden Catalysts
Neuralstem - Burning Cash, Looking For Answers
Cue Biopharma: Too Early For This Very Exciting Platform
De-Risking Catalysts Aplenty - Cara Therapeutics
Where To Next? Tigenix Investors Have New Stem Cell Options
Cleveland Biolabs' Delay Supports Competitor Advantage In Acute Radiation Syndrome
PacBio's Library Preparation Issues Announced At A Tough Time
Summit Therapeutics: Undervalued With Potential Blockbuster Pipeline
Disrupting Breast Cancer Paradigms - Odonate Therapeutics
Powerful Data Potentiates Rapid EU Market Approval For Tigenix Stem Cell Therapies
Cutting Edge Gene Therapies: Beta-Thalassemia Breakthroughs (Part I)
You Get A Dilution! You Get A Dilution! What About Crispr Therapeutics?
Relieving Suffering From Genetic Disease - Abeona Therapeutics
Catalyst Rich Pipelines - Strongest Biotech Plays For 2018
Sangamo's Powerful Pipeline Drives Significant Upside
Allena Pharmaceuticals: Complicated Phase III Filing
Crispr Therapeutics Earnings Update: Maintains The Lead In Cas9 Clinical Trials
Athersys Earnings - Anticipation Builds For A Partnership
Spero Therapeutics: An Exciting Anti-Microbial IPO
AveXis: Revolutionary Cure For SMA1 Enters Phase III Trials With Excitement Mounting
Emergence Of A Novel Gene Therapy Mechanism: Krystal Biotech
Calyxt Jumping Into A Crowded Space